{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T05:51:24Z","timestamp":1740894684381,"version":"3.38.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Cl\u00ednica Espa\u00f1ola (English Edition)"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.rceng.2025.01.001","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T17:33:58Z","timestamp":1737653638000},"page":"131-139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Analysis of clinical features and prognosis in cardiac amyloidosis patients from Spanish hospitals (2016\u20132021)"],"prefix":"10.1016","volume":"225","author":[{"given":"A.","family":"Esteban-Fern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Anguita-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Rosillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.L.","family":"Bonilla-Palomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.L.","family":"Bernal Sobrino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Del Prado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Fern\u00e1ndez P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Rodr\u00edguez Padial","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.J.","family":"Elola Somoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.rceng.2025.01.001_bib0005","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.recesp.2011.05.003","article-title":"Amyloidosis. Also a heart disease","volume":"64","author":"Garc\u00eda-Pav\u00eda","year":"2011","journal-title":"Rev Esp Cardiol"},{"issue":"1","key":"10.1016\/j.rceng.2025.01.001_bib0010","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.tcm.2017.07.004","article-title":"Cardiac amyloidosis: an update on pathophysiology, diagnosis, and treatment","volume":"28","author":"Siddiqi","year":"2018","journal-title":"Trends Cardiovasc Med"},{"issue":"2","key":"10.1016\/j.rceng.2025.01.001_bib0015","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2021-001755","article-title":"Nationwide prevalence and characteristics of transthyretin amyloid cardiomyopathy in Sweden","volume":"8","author":"Lauppe","year":"2021","journal-title":"Open Heart"},{"issue":"1","key":"10.1016\/j.rceng.2025.01.001_bib0020","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/ehf2.13110","article-title":"Prevalence of wild type transtyrethin cardiac amyloidosis in a heart failure clinic","volume":"8","author":"Lindmark","year":"2021","journal-title":"ESC Heart Fail"},{"issue":"6","key":"10.1016\/j.rceng.2025.01.001_bib0025","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.005407","article-title":"Epidemiology of cardiac amyloidosis-associated heart failure hospitalizations among fee-for-service medicare beneficiaries in the United States","volume":"12","author":"Gilstrap","year":"2019","journal-title":"Circ Heart Fail"},{"issue":"4","key":"10.1016\/j.rceng.2025.01.001_bib0030","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ejhf.2140","article-title":"Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on myocardial and pericardial diseases","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10.1016\/j.rceng.2025.01.001_bib0035","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.recesp.2019.12.017","article-title":"Clinical profile and outcome of cardiac amyloidosis in a Spanish Referral Center","volume":"74","author":"L\u00f3pez-Sainz","year":"2021","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"3","key":"10.1016\/j.rceng.2025.01.001_bib0040","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1002\/ehf2.14337","article-title":"Patients with cardiac amyloidosis are at a greater risk of mortality and hospital readmission after acute heart failure","volume":"10","author":"Berthelot","year":"2023","journal-title":"ESC Heart Fail"},{"issue":"9","key":"10.1016\/j.rceng.2025.01.001_bib0045","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1002\/ejhf.2589","article-title":"Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis","volume":"24","author":"Antonopoulos","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.rceng.2025.01.001_bib0050","unstructured":"Sistema Nacional de Salud. Registro de Atenci\u00f3n Sanitaria Especializada. Serie hist\u00f3rica CMBD-RAE. Manual de definiciones y glosario de t\u00e9rminos. Portal estad\u00edstico del SNS [actualizado a marzo de 2021]. [Accessed 11 June 2022]. Available from: https:\/\/pestadistico.inteligenciadeg.https:\/\/pestadistico.inteligenciadegestion.mscbs.es\/publicoSNS\/S\/rae-cmbd."},{"key":"10.1016\/j.rceng.2025.01.001_bib0055","unstructured":"https:\/\/www.ine.es\/dyngs\/INEbase\/listaoperaciones.htm. Instituto Nacional de Estad\u00edstica. INEBase. 2023 [Accessed 13 October 2023]. Available from: https:\/\/pestadistico.inteligenciadeg.https:\/\/pestadistico.inteligenciadegestion.mscbs.es\/publ."},{"issue":"3","key":"10.1016\/j.rceng.2025.01.001_bib0060","first-page":"93","article-title":"Principal inpatient diagnostic cost group model for medicare risk adjustment","volume":"21","author":"Pope","year":"2000","journal-title":"Health Care Financ Rev"},{"year":"2000","series-title":"Diagnostic cost group hierarchical condition category models for medicare risk adjustment. Final report to the Health Care Financing Administration under contract number 500-595-048","author":"Pope","key":"10.1016\/j.rceng.2025.01.001_bib0065"},{"issue":"11","key":"10.1016\/j.rceng.2025.01.001_bib0070","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.hlc.2022.08.002","article-title":"Prevalence and risk factors of cardiac amyloidosis in heart failure: a systematic review and meta-analysis","volume":"31","author":"See","year":"2022","journal-title":"Heart Lung Circ"},{"issue":"6","key":"10.1016\/j.rceng.2025.01.001_bib0075","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12062273","article-title":"Estimating the prevalence of cardiac amyloidosis in old patients with heart failure-barriers and opportunities for improvement: the PREVAMIC study","volume":"12","author":"Ruiz-Hueso","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.rceng.2025.01.001_bib0080","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejim.2022.05.013","article-title":"Impact of cardiac amyloidosis on outcomes of patients hospitalized with heart failure","volume":"102","author":"G\u00f6bel","year":"2022","journal-title":"Eur J Intern Med"},{"issue":"1","key":"10.1016\/j.rceng.2025.01.001_bib0085","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10741-020-10010-8","article-title":"Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges","volume":"26","author":"Bruno","year":"2021","journal-title":"Heart Fail Rev"},{"issue":"1","key":"10.1016\/j.rceng.2025.01.001_bib0090","doi-asserted-by":"crossref","DOI":"10.5334\/gh.1262","article-title":"World Heart Federation consensus on transthyretin amyloidosis cardiomyopathy (ATTR-CM)","volume":"18","author":"Brito","year":"2023","journal-title":"Glob Heart"},{"issue":"38","key":"10.1016\/j.rceng.2025.01.001_bib0095","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.rceng.2025.01.001_bib0100","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/ejhf.2532","article-title":"Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies","volume":"24","author":"Aimo","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"10.1016\/j.rceng.2025.01.001_bib0105","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1080\/03007995.2021.1913109","article-title":"Incidence rate of hospitalization and mortality in the first year following initial diagnosis of cardiac amyloidosis in the US claims databases","volume":"37","author":"Wang","year":"2021","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"10.1016\/j.rceng.2025.01.001_bib0110","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1080\/13506120600876849","article-title":"Myocardial hypertrophy and function are related to age at onset in familial amyloidotic polyneuropathy","volume":"13","author":"Suhr","year":"2006","journal-title":"Amyloid"},{"issue":"8","key":"10.1016\/j.rceng.2025.01.001_bib0115","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1212\/WNL.0000000000003001","article-title":"Cerebral amyloid angiopathy in posttransplant patients with hereditary ATTR amyloidosis","volume":"87","author":"Sekijima","year":"2016","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.rceng.2025.01.001_bib0120","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00392-022-02114-y","article-title":"Epidemiology of cardiac amyloidosis in Germany: a retrospective analysis from 2009 to 2018","volume":"112","author":"Ney","year":"2023","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.rceng.2025.01.001_bib0125","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.amjcard.2020.05.021","article-title":"Prevalence, incidence, and impact on mortality of conduction system disease in transthyretin cardiac amyloidosis","volume":"128","author":"Donnellan","year":"2020","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.rceng.2025.01.001_bib0130","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jjcc.2023.02.009","article-title":"Prevalence of ventricular arrhythmias and role of implantable cardioverter-defibrillator in cardiac amyloidosis","volume":"81","author":"Bukhari","year":"2023","journal-title":"J Cardiol"},{"issue":"1","key":"10.1016\/j.rceng.2025.01.001_bib0135","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s00392-019-01490-2","article-title":"When and how do patients with cardiac amyloidosis die?","volume":"109","author":"Escher","year":"2020","journal-title":"Clin Res Cardiol"},{"issue":"30","key":"10.1016\/j.rceng.2025.01.001_bib0140","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.rceng.2025.01.001_bib0145","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00392-023-02202-7","article-title":"One-year readmissions for circulatory diseases and in-hospital mortality after an index episode of heart failure in elderly patients. A nationwide data from public hospitals in Spain between 2016 and 2018","volume":"112","author":"Esteban-Fern\u00e1ndez","year":"2023","journal-title":"Clin Res Cardiol"},{"issue":"5","key":"10.1016\/j.rceng.2025.01.001_bib0150","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1002\/ehf2.14000","article-title":"Incidence and predictors of worsening heart failure in patients with wild-type transthyretin cardiac amyloidosis","volume":"9","author":"Ladefoged","year":"2022","journal-title":"ESC Heart Fail"},{"issue":"1","key":"10.1016\/j.rceng.2025.01.001_bib0155","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1186\/s13023-023-02962-5","article-title":"A 15-year consolidated overview of data in over 6000 patients from the Transthyretin Amyloidosis Outcomes Survey (THAOS)","volume":"18","author":"Gentile","year":"2023","journal-title":"Orphanet J Rare Dis"}],"container-title":["Revista Cl\u00ednica Espa\u00f1ola (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2254887425000050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2254887425000050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T17:31:03Z","timestamp":1740850263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2254887425000050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2254887425000050"],"URL":"https:\/\/doi.org\/10.1016\/j.rceng.2025.01.001","relation":{},"ISSN":["2254-8874"],"issn-type":[{"type":"print","value":"2254-8874"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of clinical features and prognosis in cardiac amyloidosis patients from Spanish hospitals (2016\u20132021)","name":"articletitle","label":"Article Title"},{"value":"Revista Cl\u00ednica Espa\u00f1ola (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rceng.2025.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.rce.2024.10.007","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Medicina Interna (SEMI). All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}